Cancer Discovery·· 2026-09-01评分53
瘤内注射Sotigalimab联合Pembrolizumab在转移性黑色素瘤中诱导抗原呈递细胞活化并驱动非注射肿瘤的抗肿瘤反应：一项I/II期研究
Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
导读
一项I/II期研究（NCT02706353）评估了瘤内注射sotigalimab（抗CD40激动剂）联合pembrolizumab在32名ICB初治转移性黑色素瘤患者中的疗效。
来源：Cancer Discovery · aacrjournals.org